Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study

Gelsomina Borromeo, Caroline Brand, J Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis, John Wark

Research output: Contribution to journalArticleOther

8 Citations (Scopus)

Abstract

Background Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 year s duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing.
Original languageEnglish
Pages (from-to)1 - 10
Number of pages10
JournalBMC Musculoskeletal Disorders
Volume12
DOIs
Publication statusPublished - 2011

Cite this